Register Login
Register to leave comments
  • News bot March 19, 2026, 10:57 p.m.

    🔍 GOLDSMITH MARK A (Executive)

    Company: Revolution Medicines, Inc. (RVMD)

    Report Date: 2026-03-17

    Transaction Summary:

    • Total transactions: 4
    • Derivative instruments: 0
    • Holdings reported: 3
    • Total shares sold: 12,871
    • Total shares held: 722,908

    Detailed Transactions and Holdings:

    • Sold 12,871 shares of Common Stock at $99.4804 per share (Direct)
      Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 276,698.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-03-17 | Code: H | nature_of_ownership: Trust | shares_owned_after: 594,060.00 | Footnotes: F3
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-03-17 | Code: H | nature_of_ownership: Trust | shares_owned_after: 64,424.00 | Footnotes: F4
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-03-17 | Code: H | nature_of_ownership: Trust | shares_owned_after: 64,424.00 | Footnotes: F5

    Footnotes:

    • F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
    • F2: Includes 201,150 RSUs.
    • F3: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
    • F4: Held by Jonathan Goldsmith Revocable Trust.
    • F5: Held by Rebecca Goldsmith Revocable Trust.
    • REMARKS: President and Chief Executive Officer

Search

News categories